



CONSTITUTION
Capital Partners

FOR IMMEDIATE RELEASE

**CONSTITUTION CAPITAL PARTNERS COMPLETES CO-INVESTMENT WITH
AVISTA CAPITAL PARTNERS IN ACINO HOLDING AG**

BOSTON, MA – December 6, 2013 - Constitution Capital Partners (CCP), a private equity firm focused on North American buyouts, participated as a co-investor alongside Avista Capital in a transaction involving the acquisition of a pharmaceutical company named Acino Holding AG.

About Constitution Capital Partners (CCP)

Constitution Capital Partners, based in Boston, MA, is a private equity firm that focuses on North American small to mid-cap buyouts. CCP is a disciplined, value-oriented investor with a demonstrated track record of consistently generating top quartile returns. The firm is led by an experienced, cohesive team of investment professionals with significant experience investing in both partnerships and direct investments. For more information about Constitution Capital Partners, please see: www.concp.com.

Below is a copy of the press release from Acino Holding AG discussing the investment:

**AVISTA CAPITAL PARTNERS AND NORDIC CAPITAL HOLD 93.58% OF
ACINO'S SHARE CAPITAL**

Aesch, December 6, 2013, 07.00 hrs — On October 4, 2013, Pharma Strategy Partners GmbH, a wholly-owned subsidiary of Avista Capital Partners and Nordic Capital, published a public tender offer for all publicly held registered shares of Acino Holding AG for an offer price of CHF 115 per share in cash.

Provisional final result

Until the expiration of the additional acceptance period on December 5, 2013, 16.00 hrs, 3 237 774 Acino shares have been tendered under the tender offer. It results a participation of 93.58% of the share capital and the voting rights of Acino.

Definitive announcement of the final result

The present final result is preliminary. The definitive announcement of the final result will be published on December 11, 2013 in the Neue Zürcher Zeitung and in Le Temps.

Settlement

It is intended to pay the offer price (CHF 115 per Acino share less the gross amount of any dilution effects) for the Acino shares validly tendered during the offer period and the additional acceptance period on December 12, 2013.

Sales restrictions

The tender offer is subject to the sales restrictions according to the Offer Prospectus. The Offer Prospectus and all other tender offer documents are accessible under www.pharmastrategypartners.com.

Definition of Nordic Capital

In this press release, when referring directly or indirectly to the tender offer, or the ownership of Pharma Strategy Partners GmbH, “Nordic Capital” is defined as “one of Nordic Capital Fund VII and Nordic Capital Fund VIII”. In any other context or description in this press release, “Nordic Capital” refers to “Nordic Capital Funds VII and VIII, and/or all, or some, of their predecessor funds”.

Advisors

Lazard is acting as lead financial advisor and Credit Suisse as financial advisor in the context of the public tender offer to Avista and Nordic Capital.

About Acino

Acino (SIX: ACIN), a Swiss-based pharmaceutical company, develops, manufactures and internationally markets well-proven and innovative pharmaceuticals in novel drug delivery forms. Acino is a leader in advanced drug delivery technologies with a focus on modified release oral forms, oral dispersible forms, transdermal systems and extended release parenterals, for which it also holds patents. As a partner of pharmaceutical companies worldwide, Acino supplies finished in-house developed products and/or provides customized one-stop solutions from product development and registration to contract manufacturing, packaging and logistics. Under the brand “Acino Switzerland”, Acino markets Swiss-quality medicines in up and coming economies, currently 80 countries in the Middle East, Africa, Latin America and Asia. The Acino Group, headquartered in Aesch BL, has 788 employees and generated revenues of EUR 143 million in the first half-year 2013.

About Avista Capital Partners

Avista Capital Partners is a leading private equity firm with over USD 5 billion under management. Founded in 2005, Avista’s strategy is to make controlling or influential minority investments in growth oriented energy, healthcare, communications & media, industrials, and consumer businesses. Through its team of seasoned investment professionals and industry experts, Avista seeks to partner with exceptional management teams to invest in and add value to well-positioned businesses. For more information consult www.avistacap.com.

About Nordic Capital

Nordic Capital invests in medium and large companies, primarily in the Nordic region and Germany, and in healthcare companies globally. Since 1989, Nordic Capital has supported value creation in its investments through committed ownership and by targeting strategic development and operational improvements, making Nordic Capital a leading presence in Northern European private equity. Committed capital is provided by international institutional investors, such as pension funds, asset managers and insurance companies. The Nordic Capital Funds are based in Jersey, Channel Islands and are advised by the NC Advisory companies in Sweden, Denmark, Finland, Norway, Germany and the UK. Additional information is available at www.nordiccapital.com.